Intraperitoneal LSTA1 in CRS-HIPEC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This Study is designed to test an investigational product (IP) called LSTA1 (Study drug). LSTA1 is a drug designed to improve the delivery of anti-cancer treatments, such as chemotherapy. Improved delivery of chemotherapy may result in improved anti-cancer effects when given with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases. Participants will be randomized to receive LSTA1 with HIPEC or HIPEC alone (without LSTA1) at the time of surgery.
Epistemonikos ID: f3b2b34c2d8c5d71acf6f4707f34b41af6eb1570
First added on: May 15, 2024